A compound of formula 1 and / or at least one pharmaceutically acceptable salt of said compound, wherein Apredstavlyaet CH Au Anezavisimo represent CRili N Au Asovmestno with ring B represent a 5-membered heteroaryl or heterocyclic ring, wherein said 5-membered heteroaryl or heterocycle selected izgde t represents 1, 2 or 3 iRnezavisimo selected from H, C-Ci ^ alkyl, C-alkenyl, C-Calkinila, Sarila P-C-P-membered cycloalkyl, -C (O) OR, -CN, -C (O) NRR, -NRR, NRC ( O) R, -NRS (O) R, -NRS (O) NRR, -NRC (O) OR, -NRC (O) NRR, -NO, -OR, -OC (O) R, -OC (O) NRR, -S (O) R, -S (O) NRR, halogen, haloalkyl, heteroaryl, and heterocycle and each of the foregoing alkyl, alkenyl, alkynyl, aryl, cycloalkyl, heteroaryl and heterocycle may be substituted with one or more groups independently selected from optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted cycloalkyl, -OH, , oxo, -C (O) R, -C (O) OR, -CN, -C (O) NRR, -NRR, NRC (O) R, -NRS (O) R, -NRS (O) NRR, -NRC (O) OR, -NRC (O) NRR, -NO, -OR, -S (O) R, -S (O) NRR, halogen, optionally substituted haloalkyl, optionally substituted heteroaryl and optionally substituted heterocycle provided that when Après resents a CR, Au Asovmestno with ring B is selected from structures (3), (5) or (6) represents a single bond or a double bond R is heteroaryl optionally substituted with one or oolee groups independently selected from alkyl, alkenyl, alkynyl, aryl, cycloalkyl, oxo, -C (O) R, -C (O) OR, -CN, -C (O) NRR, -NRR, NRC (O) R, -NRS (O) R, -NRS (O) NRR, -NRC (O) OR, -NRC (O) NRR, -NO, -OR, -S (O) R, -S (O) NRR, halogen, haloalkyl, heteroaryl, and heterocycle are independently selected from H, alkyl, alkenyl, alkynyl, aryl, cycloalkyl, -C (O) R, -C (O) OR, -CN, -C (O) NRR, -NRR, NRC (O) R, -NRS (O) R, -NRS (O) NRR, -NRC (O) OR, -NRC (O) NRR, -NO, -OR, -OC
